NASDAQ:CNMD - CONMED Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
Get Started
$74.27 -0.13 (-0.17 %)
(As of 06/20/2018 03:52 AM ET)
Previous Close$74.40
Today's Range$73.34 - $74.37
52-Week Range$47.41 - $74.58
Volume202,300 shs
Average Volume172,597 shs
Market Capitalization$2.09 billion
P/E Ratio39.30
Dividend Yield1.08%
Beta0.6
CONMED logoCONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for minimally invasive procedures in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers orthopedic surgery products, including sports medicine products comprising powered resection instruments, arthroscopes, reconstructive systems, tissue repair sets, and metal and bioabsorbable implants, as well as related disposable products and fluid management systems; powered surgical instruments for use in bone orthopedic, arthroscopic, oral/maxillofacial, podiatric, plastic, ENT, neurological, spinal, and cardiothoracic surgeries; sports biologics and tissue products; and surgical visualization products. It offers orthopedic surgery products under Hall, CONMED Linvatec, Concept, and Shutt brands. The company also offers general surgery product in the areas of advanced surgical comprising clinical insufflation system; electrosurgical products; endomechanical products comprising instruments, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors; and uterine manipulator (VCARE) for use in increasing the efficiency of laparoscopic hysterectomies and other gynecologic laparoscopic procedures. In addition, it offers general surgery product in the areas of endoscopic technologies, including minimally invasive diagnostic and therapeutic products; critical care products cover a line of vital signs, cardiac monitoring, and patient care products, including ECG electrodes and accessories, cardiac defibrillation and pacing pads, and suction instruments and tubing; and physician's office electrosurgical product used by dermatologists. The company's products are used by surgeons and physicians in orthopedics, general surgery, gynecology, neurosurgery, and gastroenterology. CONMED Corporation was founded in 1970 and is headquartered in Utica, New York.

Receive CNMD News and Ratings via Email

Sign-up to receive the latest news and ratings for CNMD and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electromedical equipment
Sub-IndustryHealth Care Equipment
SectorMedical
SymbolNASDAQ:CNMD
CUSIP20741010
Webwww.conmed.com
Phone315-797-8375

Debt

Debt-to-Equity Ratio0.69
Current Ratio2.15
Quick Ratio1.23

Price-To-Earnings

Trailing P/E Ratio39.30
Forward P/E Ratio34.23
P/E Growth2.98

Sales & Book Value

Annual Sales$796.39 million
Price / Sales2.61
Cash Flow$3.9973 per share
Price / Cash18.58
Book Value$22.60 per share
Price / Book3.29

Profitability

EPS (Most Recent Fiscal Year)$1.89
Net Income$55.48 million
Net Margins8.71%
Return on Equity9.46%
Return on Assets4.28%

Miscellaneous

Employees3,100
Outstanding Shares28,040,000

CONMED (NASDAQ:CNMD) Frequently Asked Questions

What is CONMED's stock symbol?

CONMED trades on the NASDAQ under the ticker symbol "CNMD."

How often does CONMED pay dividends? What is the dividend yield for CONMED?

CONMED declared a quarterly dividend on Thursday, May 24th. Stockholders of record on Friday, June 15th will be given a dividend of $0.20 per share on Thursday, July 5th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 1.08%. The ex-dividend date is Thursday, June 14th. View CONMED's Dividend History.

How were CONMED's earnings last quarter?

CONMED Co. (NASDAQ:CNMD) announced its quarterly earnings results on Wednesday, April, 25th. The medical technology company reported $0.53 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $0.43 by $0.10. The medical technology company had revenue of $202.10 million for the quarter, compared to analyst estimates of $196.51 million. CONMED had a net margin of 8.71% and a return on equity of 9.46%. The business's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.38 EPS. View CONMED's Earnings History.

When is CONMED's next earnings date?

CONMED is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for CONMED.

What guidance has CONMED issued on next quarter's earnings?

CONMED issued an update on its FY18 earnings guidance on Wednesday, April, 25th. The company provided earnings per share guidance of $2.15-$2.20 for the period, compared to the Thomson Reuters consensus EPS estimate of $2.14.

What price target have analysts set for CNMD?

3 Wall Street analysts have issued twelve-month price objectives for CONMED's stock. Their forecasts range from $46.00 to $73.00. On average, they anticipate CONMED's stock price to reach $59.50 in the next twelve months. View Analyst Ratings for CONMED.

What are Wall Street analysts saying about CONMED stock?

Here are some recent quotes from research analysts about CONMED stock:
  • 1. According to Zacks Investment Research, "CONMED exited the first quarter of 2018 with strong top-line growth and margin expansion. Strong performances by Advanced Surgical and Endoscopic Technologies buoy optimism. We are also upbeat about the continued innovation undertaken by the company over the last year. Solid revenue guidance is indicative of brighter prospects. CONMED is also benefiting from the increasing trend of using minimally invasive techniques as a large percentage of the company’s products are designed for these procedures. CONMED outperformed the industry in a year’s time. CONMED operates in a highly competitive environment, especially in the General Surgery business. Lower healthcare spending buoyed by the foreign exchange volatility is a headwind. Moreover, CONMED’s stock looks much overvalued at the moment. Pricing pressures add to the woes. Long-term debt at the end of the just-reported first quarter was also high, raising concerns." (4/27/2018)
  • 2. Needham & Company LLC analysts commented, "We hosted investor meetings in Boston with CNMD’s CEO and CFO earlier this week. We believe that CNMD is making progress in its turnaround, as evidenced by its organic revenue growth of 3% year-to-date (YTD), which is a considerable improvement from the bottom of (3%) growth in 2H14. We expect further improvement in its domestic Orthopedic Surgery business as new products continue to gain momentum and believe that this can push overall revenue growth towards 5%. We also believe that margin expansion will be the next chapter in the CNMD story given higher revenue growth, a reduced currency headwind, and a renewed focus on cost reductions. CNMD’s operating margin is currently around 9% and we see potential for this to reach the mid-teens or higher over time. We think the stock looks undervalued at a P/E of 25.5x our 2018E estimate considering that we think its potential earnings power is $3.00+ per share and we reiterate our Buy rating." (11/17/2017)

Who are some of CONMED's key competitors?

Who are CONMED's key executives?

CONMED's management team includes the folowing people:
  • Mr. Curt R. Hartman, CEO, Pres & Director (Age 54)
  • Mr. Patrick J. Beyer, Pres of CONMED International (Age 52)
  • Mr. Stanley W. Peters III, VP & GM of U.S. Advanced Surgical (Age 43)
  • Mr. Nathan Folkert, VP & GM of U.S. Orthopedics (Age 43)
  • Mr. Todd W. Garner, Exec. VP & CFO (Age 49)

Has CONMED been receiving favorable news coverage?

Headlines about CNMD stock have been trending somewhat negative this week, according to Accern. The research firm ranks the sentiment of news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CONMED earned a news impact score of -0.02 on Accern's scale. They also gave media coverage about the medical technology company an impact score of 40.10 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.

Who are CONMED's major shareholders?

CONMED's stock is owned by many different of retail and institutional investors. Top institutional investors include BlackRock Inc. (12.69%), Scopia Capital Management LP (7.75%), Dimensional Fund Advisors LP (7.40%), SCOPIA CAPITAL MANAGEMENT LP (6.60%), Victory Capital Management Inc. (6.46%) and Champlain Investment Partners LLC (4.72%). Company insiders that own CONMED stock include Charles Farkas, Curt R Hartman, Daniel Jonas, Dirk Kuyper, Heather L Cohen, Jo Ann Golden, Luke A Pomilio, Mark E Tryniski, Nathan Folkert and Terence M Berge. View Institutional Ownership Trends for CONMED.

Which institutional investors are selling CONMED stock?

CNMD stock was sold by a variety of institutional investors in the last quarter, including Scopia Capital Management LP, Victory Capital Management Inc., Champlain Investment Partners LLC, Dimensional Fund Advisors LP, Thrivent Financial for Lutherans, Westwood Holdings Group Inc., Citadel Advisors LLC and Lord Abbett & CO. LLC. Company insiders that have sold CONMED company stock in the last year include Daniel Jonas, Jo Ann Golden, Luke A Pomilio, Nathan Folkert and Terence M Berge. View Insider Buying and Selling for CONMED.

Which institutional investors are buying CONMED stock?

CNMD stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., WINTON GROUP Ltd, Prudential Financial Inc., Hsbc Holdings PLC, Prescott Group Capital Management L.L.C., Epoch Investment Partners Inc., Summit Global Investments and A.R.T. Advisors LLC. Company insiders that have bought CONMED stock in the last two years include Charles Farkas, Curt R Hartman, Heather L Cohen and Mark E Tryniski. View Insider Buying and Selling for CONMED.

How do I buy shares of CONMED?

Shares of CNMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is CONMED's stock price today?

One share of CNMD stock can currently be purchased for approximately $74.27.

How big of a company is CONMED?

CONMED has a market capitalization of $2.09 billion and generates $796.39 million in revenue each year. The medical technology company earns $55.48 million in net income (profit) each year or $1.89 on an earnings per share basis. CONMED employs 3,100 workers across the globe.

How can I contact CONMED?

CONMED's mailing address is 525 FRENCH ROAD, UTICA NY, 13502. The medical technology company can be reached via phone at 315-797-8375.


MarketBeat Community Rating for CONMED (CNMD)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  263 (Vote Outperform)
Underperform Votes:  195 (Vote Underperform)
Total Votes:  458
MarketBeat's community ratings are surveys of what our community members think about CONMED and other stocks. Vote "Outperform" if you believe CNMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/20/2018 by MarketBeat.com Staff
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.